Original Publication Date: 1 March, 2015
Publication / Source: Immunotherapy
Authors: Michela Croce, Maria Valeria Corrias, Valentina Rigo & Silvano Ferrini
The prognosis of high-risk neuroblastoma (NB) is still poor, in spite of aggressive multimodal treatment. Recently, adjuvant immunotherapy with anti-GD2 antibodies combined with IL-2 or GM-CSF has been shown to improve survival. Several other immunotherapy strategies proved efficacy in preclinical models of NB, including different types of vaccines, adoptive cell therapies and combined approaches.